Replies to post #11388 on BioCurex, Inc.(fka BOCX)

[opportunityknocking]

We better have air tight patents on recaf, because all of the pharmaceutical companies will want to use recaf to target their drugs.
As soon as recaf is approved, I would invest in the healthcare insurers, because they will save billions in unnecessary testing and surgery.
There will be a moral issue among the healthcare providers, because recaf will eliminate the need for pap smears, mamograms, colonoscopies, thyroid biopsies, and a number of other routine abused tests. This in turn will lead to substantially fewer surgeries and will result in lower salaries for doctors and hospitals. They should charge a fair price for recaf, because it is a win-win situation for the patient and the insurance companies.
I expect alot of contoversy when the test comes out, and there will always be individuals giving false information, because of their own agenda.
We will almost instantly be approached for collaborations to experiment with recaf by many different universities, research centers and pharmaceutical companies.
Our patents are the most prized possession other than Dr Moro, therefore, we have to vigorously defend what is rightfully ours. Anyone using our recaf marker for any reason must be required to be under contract with fiduciary responsibilities. We should be able to capitalize on all fronts if the patents are done properly.
About Roche buying Ventana Medical...I also know that Ventana was a 5 dollar stock not too many years ago and now is being bought for 3.4 billion dollars or almost 90 dollars a share. If it makes sense someone will want us, but at this stage we would be severely undervalued. Fast forward 5 years from now (which many of us have already been involved with BioCurex for 5 years already), and we will fetch a price like Ventana.
I think I know the person buying on Friday may have been the person I spoke to from Quest Diagnostics, because he seemed very excited about the information I presented to him. I'll ask him when I speak with him next week when I follow up on what he thought and what he plans to do about it.